弥漫型腱鞘巨细胞瘤患者的手术结局:一项国际回顾性队列研究
这项国际多中心回顾性队列研究纳入31家肉瘤参考中心1990年至2017年连续治疗的弥漫型腱鞘巨细胞瘤患者,966例手术患者中位随访54个月,局部复发425例(44%),3年、5年、10年无复发生存率分别为62%、55%、40%,手术并发症报告于105/906例(12%)。
要点
- 966例手术患者中位随访54个月,局部复发425例(44%)。
- 3年、5年、10年无复发生存率分别为62%、55%、40%。
- 手术并发症报告于906例有完整数据患者中的105例(12%)。
核心结论
- 弥漫型腱鞘巨细胞瘤的手术治疗并非对每位患者都是确定性治疗,因为局部复发风险高且术后并发症风险相对较高。
- 在初治患者手术后,作者认为在迄今最大队列中未能识别出个体患者局部复发的危险因素。
研究设计与样本
- 国际多中心回顾性队列研究,纳入31家肉瘤参考中心1990年1月1日至2017年12月31日连续治疗的任何年龄、组织学证实的大关节弥漫型腱鞘巨细胞瘤患者,排除局限型患者。
- 分析仅纳入入院状态、治疗日期、参与中心治疗类型及治疗后首次局部复发核心标准数据完整的患者;共收到1192例患者记录,其中966例(81%)接受手术治疗且核心标准信息完整。
- 采用非参数方法估计三级中心初次手术切除后3年、5年和10年无复发生存率,采用多因素Cox回归模型估计危险因素效应,并按初诊疾病状态(原发 vs 复发)和手术类型(开放手术 vs 关节镜滑膜切除术)进行亚组分析。
主要发现
- 1192例患者中758例(64%)有膝关节受累,1163例有手术类型完整数据的患者中628例(54%)接受一期开放滑膜切除术。
- 966例手术治疗患者中位随访54个月(IQR 27-97),425例(44%)发生局部复发。
- 无复发生存率3年为62%(95%CI 59-65),5年为55%(51-58),10年为40%(35-45)。
- 906例有手术并发症完整数据的患者中105例(12%)报告手术并发症。
- 434例有疼痛数据患者中255例(59%)术后疼痛改善,453例有肿胀数据患者中328例(72%)术后肿胀改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse-type tenosynovial giant-cell tumour is a rare, locally aggressive, and difficult-to-treat soft tissue tumour. Clinical and surgical outcomes depend on multiple factors, including preoperative diagnostic assessment, the localisation and extent of disease, and possibly the choice of treatment modalities by orthopaedic surgeons. We did a retrospective cohort study to characterise global surgical treatment protocols, and assess surgical outcomes, complications, and functional results in patients with diffuse-type tenosynovial giant-cell tumours. METHODS: In this international, multicentre, retrospective cohort study, we included consecutive patients treated in 31 sarcoma reference centres between Jan 1, 1990, and Dec 31, 2017. Eligible patients were of any age and had histologically proven diffuse-type tenosynovial giant-cell tumour of large joints. Patient data were retrieved from the local databases of participating centres. Patients with localised-type tenosynovial giant-cell tumour were excluded. In the analysis, we only included patients with complete core criteria data regarding admission status, date of treatment, type of treatment at participating centre, and first local recurrence after treatment. We used a non-parametric method to estimate recurrence-free survival at 3, 5, and 10 years after initial surgical resection in a tertiary centre. We used a multivariate Cox regression model to estimate the effect of risk factors. We also present subgroup analyses of disease status at presentation (primary vs recurrent disease) and recurrence-free survival by surgery type (open surgery vs arthroscopic synovectomy), and prespecified risk factors were tested in a univariate and multivariable analyses, with an endpoint of first local recurrence after treatment in a tertiary centre. FINDINGS: Data collection for these analyses occurred between January, 2016, and May, 2018. We received the records of 1192 patients, of which 966 (81%) were surgically treated and had complete information on core criteria. 445 patients were admitted with therapy-naive disease of the knee and were primarily treated in a tertiary centre. Since patients with wait and see treatment do not have a starting date of treatment, these patients were excluded in the calculation of median follow-up time for all patients. For this calculation we used time of surgery as a starting date. 758 (64%) of 1192 patients had knee involvement and 628 (54%) of 1163 patients with complete data on type of surgery had one-staged open synovectomy. At a median follow-up of 54 months (IQR 27-97), recurrent disease developed in 425 (44%) of all 966 surgically treated cases, and recurrence-free survival was 62% (95% CI 59-65) at 3 years, 55% (51-58) at 5 years, and 40% (35-45) at 10 years. Surgical complications were reported in 105 (12%) of 906 patients who had complete data on surgical complications. Pain improved after surgical treatment in 255 (59%) of 434 patients and swelling improved in 328 (72%) of 453 patients who had complete data. INTERPRETATION: This study of patients with diffuse-type tenosynovial giant-cell tumour provides a comprehensive and up-to-date disease overview, assessing the clinical profile and management of the disease in multiple specialised referral centres. Surgical treatment of diffuse-type tenosynovial giant cell tumours is not a definitive treatment for every patient because it involves a high risk for local recurrent disease and a relatively high risk for postoperative complications. After surgical treatment in treatment-naive patients, risk factors for recurrent disease in individual patients were not identified in what we believe is the largest cohort to date. FUNDING: Daiichi Sankyo.
引用
- Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019. PMID: 31029509. doi:10.1016/S1470-2045(19)30100-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。